▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / JAZZ

JAZZ — Jazz Pharmaceuticals plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1232524 · Ireland
Last close
$229.19
Market Cap
$14.38B
52W High
$243.32
52W Low
$177.58
ADV30
933,833
Next earnings
2026-08-04
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,068,900,000 934,800,000 336,600,000 293,100,000 11,859,600,000 1,844,300,000 7,327,300,000
Dec 2025 1,197,926,000 1,044,398,000 254,535,000 203,451,000 11,659,340,000 1,391,899,000 7,340,756,000
Sep 2025 1,126,107,000 997,227,000 100,009,000 251,412,000 11,356,485,000 1,326,070,000 7,397,455,000
Jun 2025 1,045,712,000 929,444,000 218,970,000 -718,470,000 10,944,141,000 1,189,880,000 7,237,782,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,334,173,000
Investing CF
$-1,217,813,000
Financing CF
$-138,380,000
CapEx
$-190,552,000
Dividends Paid
—
Buybacks
$-150,001,000
EPS Diluted TTM
$-0.02
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$939,200,000
Inventory
$437,500,000
Receivables
$836,300,000
ST Investments
$1,030,000,000
EBIT TTM
$-37,603,000
Pretax Income TTM
$-218,848,000
Interest Exp TTM
$181,245,000
Analysts
17

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,438,686,208
EBITDA
$2,008,267,008
Free Cash Flow
$1,335,671,424
Enterprise Value
$16,922,627,072
Total Cash
$2,874,299,904
Total Debt
$5,416,900,096
Shares Out
62,742,820
Trailing EPS
$0.11
Book Value
$72.28
ROE
0.7%
ROA
6.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 4,267,586,000 517,622,000 -356,148,000 11,659,340,000 7,340,756,000 — 1,355,773,000
Dec 2024 4,068,950,000 726,630,000 560,120,000 12,012,257,000 7,918,501,000 — 1,395,908,000
Dec 2023 3,834,204,000 597,580,000 414,832,000 11,393,359,000 7,656,362,000 — 1,092,007,000
Dec 2022 3,659,374,000 512,268,000 -224,060,000 10,835,255,000 7,749,521,000 — 1,271,977,000

TTM Snapshot

Revenues TTM
$3,805,876,000
NetIncome TTM
$289,394,000
OpCashFlow TTM
$0
Assets (Latest)
$12,012,257,000
Forward EPS
$25.58

Max Pain — expiry 2026-06-18

max pain strike: $160.00 · spot: $229.19 · call oi: 2,027 · put oi: 681
Expected Move to 2026-06-18: ±$12.49 (5.45%) — implied range $216.70 – $241.68 · ATM straddle on $230.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GNMSF GENMAB A/S $15.29B $249.00 —
GMAB GENMAB A/S $15.41B $25.10 —
BBIO BridgeBio Pharma, Inc. $13.26B $67.68 —
ASND Ascendis Pharma A/S $13.17B $213.23 —
AXSM Axsome Therapeutics, Inc. $12.64B $245.64 —

News headlines (Yahoo Finance, 1h cache)

3 Unpopular Stocks We Find Risky
2026-06-08 09:33 · Yahoo
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narco
2026-06-04 11:45 · Yahoo
Jazz Pharmaceuticals PLC (JAZZ): CBD-Based Epidiolex Drug Sales Up 15%
2026-05-31 12:15 · Yahoo
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
2026-05-30 17:56 · Yahoo
3 Healthcare Stocks We Think Twice About
2026-05-29 18:24 · Yahoo
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
2026-05-28 20:27 · Yahoo
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally A
2026-05-27 21:00 · Yahoo
3 Mid-Cap Stocks We’re Skeptical Of
2026-05-25 10:59 · Yahoo
Banking giant massively resets Jazz Pharma stock price target
2026-05-23 18:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →